All In Biotech

Drug Trial Radar · NCT03599791

DYmista NAsal Spray in CHInese Patients

Multicentre, Randomized, Double-blind, Parallel Group Phase III Study to Assess Efficacy and Safety of Dymista® Compared to Azep® and Flixonase® Nasal Sprays in the Treatment of Chinese Patients With Allergic Rhinitis/Rhinoconjunctivitis

Last checked: Nov 19, 2026Latest source record: Feb 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

900

Actual

Start

Jun 29, 2018

Primary completion

Sep 24, 2019

Study completion Sep 24, 2019

Sponsor

Lead sponsor
MEDA Pharma GmbH & Co. KGIndustry
Sponsor type
Industry
First posted
Jul 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase III clinical study to assess the efficacy and safety of Dymista® Nasal Spray in comparison to Azep® nasal spray and Flixonase® nasal spray in Chinese patients aged ≥ 12 years with moderate-to-severe allergic rhinitis/rhinoconjunctivitis.

Conditions

  • Allergic Rhinitis

Interventions

  • Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUATDrug

    Dymista Nasal spray suspension

  • Azelastine Hydrochloride 0.137 MG/ACTUATDrug

    AZEP Nasal spray solution

  • Fluticasone Propionate 0.05 MG/ACTUATDrug

    Fluticasone propionate nasal spray suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combined 12-hour rTNSS (AM + PM)Time frame: 14 days

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site 2

    Beijing, Beijing Municipality, China

  • Investigational Site 3

    Beijing, Beijing Municipality, China

  • Investigational Site 4

    Beijing, Beijing Municipality, China

  • Investigational Site 5

    Beijing, Beijing Municipality, China

  • Investigational Site

    Chongqing, Chonqing, China

  • Investigational Site 1

    Beijing, Dongcheng District, China

  • Investigational Site 1

    Guangzhou, Guangdong, China

  • Investigational Site 2

    Guangzhou, Guangdong, China

  • Investigational Site 1

    Wuhan, Hubei, China

  • Investigational Site 2

    Wuhan, Hubei, China

  • Investigational Site

    Changsha, Hunan, China

  • Investigational Site

    Nanchang, Jiangxi, China

  • Investigational Site

    Changchun, Jilin, China

  • Investigational Site

    Tonghua, Jilin, China

  • Investigational Site

    Yanbian, Jilin, China

  • Investigational Site

    Jining, Jining, China

  • Investigational Site

    Dalian, Liaoning, China

  • Investigational Site

    Nanjing, Nanjing, China

  • Investigational Site 1

    Qingdao, Shandong, China

  • Investigational Site 2

    Qingdao, Shandong, China

  • Investigational Site

    Yantai, Shangdong, China

  • Investigational Site

    Zibo, Shangdong, China

  • Investigational Site

    Shanghai, Shanghai Municipality, China

  • Investigational Site

    Changzhi, Shanxi, China

  • Investigational Site

    Taiyuan, Shanxi, China

  • Investigational Site 1

    Xi’an, Shanxi, China

  • Investigational Site 2

    Xi’an, Shanxi, China

  • Investigational Site

    Chengdu, Sichuan, China

  • Investigational Site 1

    Tianjin, Tianjin Municipality, China

  • Investigational Site 2

    Tianjin, Tianjin Municipality, China

  • Investigational Site 3

    Tianjin, Tianjin Municipality, China

  • Investigational Site 4

    Tianjin, Tianjin Municipality, China

  • Investigational Site

    Ürümqi, Xianjiang Uygur, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.